Alexander Disease (AxD) is a rare fatal neurodegenerative disorder that is attributed to mutations in glial fubrillary acidic protein (GFAP). Clinically, AxD is considered a type of leukoencephalopathy sometimes characterized by demyelination of the central nervous system (CNS) and the formation of GFAP-containing Rosenthal fibers in astrocytes. While it has been shown that GFAP mutations cause AxD, the exact pathomechanism is still unknown and there is still no accepted line of treatment. The present invention provides a new approach for AxD therapy based on the newly indentified role of GFAP in the unconventional secretory pathway (USP).
Further information: PDF
Phone: +49 (0)208/94105 10
Dipl.-Ing. Alfred Schillert
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
email@example.com | TechnologieAllianz e.V.
New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.
Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
22.08.2017 | Health and Medicine
22.08.2017 | Materials Sciences
22.08.2017 | Life Sciences